An ongoing and global Phase 3 clinical trial program for oral tavapadon, a selective dopamine receptor agonist aiming to improve motor function in people with Parkinson’s disease, expects to release study findings next year. Three separate, 27-week trials are evaluating tavapadon’s efficacy, safety, and tolerability against…
News
Swallowing problems can cause deadly complications for people with Parkinson’s disease, if not handled appropriately, making it critical that hospital clinicians partner with caregivers to help address the needs of patients. That’s the argument made by Annie Brooks, director of strategic initiatives at the Parkinson’s Foundation, in “Dysphagia…
Scientists in Thailand have developed lightweight gloves that help to lessen the tremors affecting daily life for people with Parkinson’s disease. The gloves currently are available at King Chulalongkorn Memorial Hospital in Bangkok, but the researchers plan to partner with entrepreneurs to further refine the devices. One goal is…
Exposure to low oxygen may help to ease the symptoms of Parkinson’s disease — but a lot more research is needed to conclusively determine the safety and effectiveness of this strategy for use among people with the neurodegenerative disorder, according to a new report. “From a clinical perspective, hypoxia…
The U.S. Food and Drug Administration (FDA) has accepted Supernus Pharmaceuticals‘ new application seeking approval of its apomorphine infusion pump — known as SPN-830 — to treat motor fluctuations in people with Parkinson’s disease. A decision on the company’s request, resubmitted last month in the form…
Being diagnosed with depression or having symptoms of the condition significantly increases the risk for developing Parkinson’s disease, according to a study of nearly 100,000 elderly people in South Korea. The association was the greatest for people with a diagnosis of depression and subjective depressive symptoms. Their risk nearly…
EvokAI Creative Labs’ Movement Disorder Monitor (MDM) Flex Sensor — which uses artificial intelligence (AI) in monitoring abnormal body movements — has received CE Mark approval in Europe for the management of Parkinson’s disease and other movement disorders. CE Mark approval indicates that the sensor has been assessed…
Exposure to an air pollutant called fine particular matter (PM2.5) is significantly associated with an increased risk of developing Parkinson’s disease, according to a U.S. population study. “Using state-of-the-art geospatial analytical techniques, we were, for the first time, able to confirm a strong nationwide association between incident Parkinson’s disease…
Engaging in regular physical activity before and after being diagnosed with depression can lower a person’s risk of developing Parkinson’s disease, while stopping to exercise increases that risk, a large study that followed patients in South Korea for about five years reports. Becoming more active only after a depressive…
Enrollment is now complete for a Phase 2 trial that’s assessing the safety and efficacy of oral vodobatinib (K0706), an experimental Abl inhibitor, in people with early Parkinson’s disease across 84 clinical sites in the U.S., Europe, and India. The placebo-controlled trial (NCT03655236), dubbed PROSEEK and sponsored by Sun…
Recent Posts
- Blocking 2 proteins could slow Parkinson’s progression: Study
- How to minimize stress while traveling with Parkinson’s disease
- New PET tracer helps scientists ‘see’ Parkinson’s toxic protein clumps
- Tech duo to advance brain-penetrating drugs for CNS disorders
- New trial offers extended buntanetap access for people with Parkinson’s